Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2025

IDL Diagnostics
Lataa tiedote

The Nomination Committee proposes the election of Professor Per-Anders Abrahamsson as a new board member for AroCells Board of Directors at the 2025 Annual General Meeting.

Professor Per-Anders Abrahamsson (born in 1949) is a medical doctor and urologist with 45 years of experience as a specialist focusing on urinary tract cancer and holds a professorship at Lund University in urological oncology. He has served as clinic manager in Malmö and Lund for 20 years and as Secretary General for the world-leading scientific organization European Association of Urology from 2007 to 2015. Per-Anders Abrahamsson has previously served on the boards of both AroCell and IDL Biotech. He is currently a board member at Perituskliniken AB.

The nomination committee´s proposal for the board at the AGM is the re-election of Eva Nordström, Agneta Tufvesson Alm, Clas Runnberg, and Max Pihlqvist, and the new election of Per-Anders Abrahamsson. Fredrik Lindgren has declined re-election to the board.

The Nomination Committee proposes the re-election of Max Pihlqvist as the Chairman of the Board.
 
Other proposals from the Nomination Committee will be provided in the notice for the Annual General Meeting.

AroCells Nomination Committee consists of:
Jon Eiken (Chairman)
Jerker Swanstein
Didrik Hamilton

Contacts


Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell


AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments


The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2025

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.